- Home
- REBN vs BLRX Comparison
REBN vs BLRX Comparison
Compare REBN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- BLRX
- Stock Information
- Founded
- REBN 2015
- BLRX 2003
- Country
- REBN United States
- BLRX Israel
- Employees
- REBN N/A
- BLRX N/A
- Industry
- REBN Restaurants
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- BLRX Health Care
- Exchange
- REBN Nasdaq
- BLRX Nasdaq
- Market Cap
- REBN 12.8M
- BLRX 15.3M
- IPO Year
- REBN 2022
- BLRX 2011
- Fundamental
- Price
- REBN $2.64
- BLRX $4.41
- Analyst Decision
- REBN
- BLRX Strong Buy
- Analyst Count
- REBN 0
- BLRX 2
- Target Price
- REBN N/A
- BLRX $19.00
- AVG Volume (30 Days)
- REBN 79.0K
- BLRX 49.9K
- Earning Date
- REBN 08-18-2025
- BLRX 08-14-2025
- Dividend Yield
- REBN N/A
- BLRX N/A
- EPS Growth
- REBN N/A
- BLRX N/A
- EPS
- REBN N/A
- BLRX N/A
- Revenue
- REBN $6,103,732.00
- BLRX $22,340,000.00
- Revenue This Year
- REBN $335.98
- BLRX N/A
- Revenue Next Year
- REBN N/A
- BLRX N/A
- P/E Ratio
- REBN N/A
- BLRX N/A
- Revenue Growth
- REBN 3.38
- BLRX 91.68
- 52 Week Low
- REBN $1.03
- BLRX $2.30
- 52 Week High
- REBN $8.30
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- REBN 47.06
- BLRX 46.95
- Support Level
- REBN $2.40
- BLRX $4.47
- Resistance Level
- REBN $3.10
- BLRX $4.74
- Average True Range (ATR)
- REBN 0.21
- BLRX 0.30
- MACD
- REBN -0.02
- BLRX -0.04
- Stochastic Oscillator
- REBN 30.80
- BLRX 33.17
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.